SAINT LAURENT, QUEBEC, Oct. 6, 2009 - IntelGenx Technologies Corp. ("IntelGenx") (TSX-V: IGX) (OTC.BB:IGXT) announced today that the exercise price of the stock options granted to Little Gem Life Science Partners (“Little Gem”), as announced in IntelGenx’ press release dated October 1, 2009, has been established at CAD$0.60 per share. The price was determined by the closing price of IntelGenx shares on the TSX Venture Exchange on October 2nd, 2009.

About IntelGenx Technologies Corp.
IntelGenx Technologies Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. Intelgenx's research and development pipeline includes products for the treatment of pain, hypertension, osteoarthritis and depressive disorders. More information is available about the company at www.intelgenx.com.

The TSX Venture Exchange and OTC Bulletin Board have not reviewed and do not accept responsibility for the adequacy or accuracy of this release.

IntelGenx Technologies Corp.
Dr. Horst G. Zerbe
President and CEO
514-331-7440 (ext. 201)
514-331-0436 (FAX)
This email address is being protected from spambots. You need JavaScript enabled to view it.